Revised D-A-CH reference values for the intake of biotin

Alexandra Jungert1 · Sabine Ellinger2 · Bernhard Watzl3 · Margrit Richter4 on behalf of the German Nutrition Society (DGE)

Received: 10 March 2021 / Accepted: 25 November 2021 / Published online: 3 January 2022 © The Author(s) 2021, corrected publication 2022

Abstract

Purpose The reference values for biotin intake for Germany, Austria and Switzerland lead back to a report in 2000. Following a timely update process, they were revised in 2020.

Methods For infants aged 0 to < 4 months, adequate biotin supply via human milk was assumed and in consequence the reference value reflects the amount of biotin delivered by human milk. For infants aged 4 to < 12 months, biotin intake was extrapolated from the reference value for younger infants. Due to missing data on average requirement, the reference values for biotin intake for children, adolescents and adults were derived based on observed intake levels. The reference value for lactating women considered in addition biotin losses via human milk.

Results The reference value for biotin intake for infants aged 0 to < 4 months was set at 4 µg/day and for infants aged 4 to < 12 months at 6 µg/day. In children and adolescents, the reference values for biotin intake ranged from 20 µg/day in children 1 to < 4 years to 40 µg/day in youths 15 to < 19 years. For adults including pregnant women, 40 µg/day was derived as reference value for biotin intake. For lactating women, this value was set at 45 µg/day.

Conclusions As deficiency symptoms of biotin do not occur with a usual mixed diet and the average requirement cannot be determined, reference values for an adequate biotin intake for populations from Germany, Austria and Switzerland were derived from biotin intake levels assessed in population-based nutrition surveys.

Keywords Biotin · Reference values · Dietary intake

Introduction

The reference values for biotin intake for Germany [D], Austria [A] and Switzerland [CH] lead back to a report in 2000 [1]. Following a timely update process, the reference values for biotin intake were recently revised and published in German language in autumn 2020 [2]. The present paper provides a summary of this publication.

Biotin is a water-soluble, sulfur-containing vitamin of the B-group [3] that acts as covalently bound coenzyme of acetyl-CoA carboxylase (ACC, two isoforms), pyruvate carboxylase (PC), β-methylcrotonyl-CoA carboxylase (MCC) and propionyl-CoA carboxylase (PCC) [4]. These enzymes are involved in the synthesis of fatty acids and cholesterol, in gluconeogenesis and in the catabolism of odd-chain fatty acids and branched amino acids (leucine, isoleucine, valine) as well as methionine and threonine [3, 4]. Through biotinylation of histones, biotin is involved in the regulation of gene expression, cell proliferation, repair of DNA damages [5] and in the stability of the chromatin structure [6].
Diet-related biotin deficiency is rare. An unbalanced diet with a high proportion of raw egg white [3, 7] or total parenteral nutrition without an adequate biotin supplementation may cause biotin deficiency [8–10]. Lifestyle factors may also favour biotin deficiency. Chronic alcohol abuse inhibits biotin absorption [11], while smoking probably promotes biotin degradation [12]. Since anticonvulsants impair intestinal absorption of biotin [13] and enhance biotin catabolism [14, 15], an increased biotin requirement during long-term antiepileptic therapy can be assumed. Congenital defects of biotinidase and carboxylases as well as inflammatory bowel disease may also cause functional biotin deficiency [11].

In general, clinical signs assigned to biotin deficiency are rather unspecific for biotin and may also be seen for other vitamins of the B-group. They comprise growth retardation, dermatological symptoms such as seborrheic dermatitis and alopecia, conjunctivitis [16] as well as neurological disorders like ataxia, lethargy and paraesthesia [11, 16]. Furthermore, an impairment of the humoral and cellular immune response due to biotin deficiency has been observed [3, 4, 17]. Clinical symptoms of biotinidase deficiency additionally include seizures, hypotension, metabolic ketoacidosis, hearing loss and optic atrophy leading to impaired vision [18–20]. As holocarboxylase synthetase is needed for the binding of biotin to apocarboxylases, holocarboxylase synthetase deficiency leads to metabolic ketoacidosis within the first week of life, accompanied by lethargy, muscular hypotension, vomiting and dermatological symptoms [21].

Adverse effects in humans due to high-dose biotin supplementation (up to 20 mg/day) have not been observed [3, 22]. The usual biotin intake via food and supplements does not represent a health risk to humans [23]. However, according to the Institute of Medicine (IOM) [24] and the European Food Safety Authority (EFSA) [23], data regarding adverse health effects of very high biotin intake are insufficient to derive a tolerable upper intake level.

The revised reference values for biotin intake are assumed 1) to prevent deficiency-related conditions in nearly all healthy individuals within the population, 2) to ensure optimal physiological and psychological performance and 3) to facilitate the formation of body reserves [2]. The D-A-CH reference values are divided into three categories: recommended intake values, estimated values for an adequate intake and guiding values. Information on the average requirement is necessary to derive recommended intake values, which – per definition – meet the requirement of approximately 98% of the population, stratified by sex and age (this term corresponds to Recommended Dietary Allowance of IOM and to Population Reference Intake of EFSA). In case of insufficient information on the average requirement, estimated values for an adequate intake are given, which are usually based on observed or experimentally assessed nutrient intake levels of apparently healthy, well-nourished subjects of a defined population group (this term corresponds to Adequate Intake of IOM and EFSA). The term “estimated” underlines the uncertainty of this methodological procedure. Nevertheless, estimated values for an adequate intake are expected to provide still an appropriate information for a sufficient and safe intake. Guiding values are given for non-essential components in food with regard to preventive effects, but also for components with a highly variable requirement due to many influencing factors preventing the derivation of recommended intake values or estimated values for an adequate intake [2, 25]. The reference values for biotin are estimated values for an adequate intake (see “Derivation of the reference values for biotin intake” and Table 1).

### Biotin absorption and metabolism

In food, biotin is present in unbound (free) or protein-bound form; the latter is predominantly found in meat and cereals [4, 16]. Free biotin is almost completely absorbed [22, 26, 27]. Protein-bound biotin can be absorbed in free form which requires cleavage by gastrointestinal proteases and peptidases to biocytin (ε-Ν-biotyl-L-lysine) and biotinyl peptides [3] and subsequent release of biotin via biotinidase [3, 18]. Avidin, a glycoprotein in raw egg white, strongly binds to biotin, and thus inhibits intestinal biotin absorption [28]. Heat exposure denatures avidin in egg white, preventing the complex formation and thus allowing biotin absorption [16].

| Table 1 Estimated values for an adequate intake of biotin |
|---------------------------------|----------------|
| Age                         | Biotin (µg/day) |
| Infants                      |                |
| 0 to under 4 months          | 4              |
| 4 to under 12 months         | 6              |
| Children and adolescents     |                |
| 1 to under 4 years           | 20             |
| 4 to under 7 years           | 25             |
| 7 to under 10 years          | 25             |
| 10 to under 13 years         | 35             |
| 13 to under 15 years         | 35             |
| 15 to under 19 years         | 40             |
| Adults                       |                |
| 19 to under 25 years         | 40             |
| 25 to under 51 years         | 40             |
| 51 to under 65 years         | 40             |
| 65 years and older           | 40             |
| Pregnant women               | 40             |
| Lactating women              | 45             |
Biotin is mainly absorbed in the small intestine [26, 29] and to a smaller extent in the proximal colon [26]. The absorption rate is higher during conditions of biotin deficiency or low biotin intake compared to adequate biotin status or pharmacological doses of biotin supply [11, 30]. At present, no data are available on the average bioavailability of biotin from a usual mixed diet.

In addition to biotin intake via food and supplements, biotin synthesis by intestinal microbiota may contribute to cover the biotin requirement. However, its contribution to biotin supply is still unclear [11].

Biotin uptake by epithelial cells of the intestinal brush-border membrane is mediated through a saturable sodium-dependent carrier [31], which also transports other vitamins such as pantothenic acid, and thus is called human sodium-dependent multivitamin transporter (hSMVT) [3, 32]. During supplementation with biotin at pharmacological doses, absorption will mainly occur via passive diffusion [33].

Biotin is transported across the basolateral membrane by a sodium-independent carrier-mediated system [29]. More than 80% of biotin circulates freely in plasma [4, 34], whereas a small proportion is reversibly or covalently bound to proteins (e.g., biotinidase) [4, 18, 19, 35]. The valeric acid side chain of biotin can be covalently bound to a lysyl residue of apoenzymes by the holocarboxylase synthetase, resulting in the synthesis of active carboxylases [3, 36, 37]. Proteolytic degradation of carboxylases allows the recycling of biotin [19]. Renal reabsorption of biotin is regulated via hSMVT [38]. The liver is the primary storage organ [3]. At present, data on the average biotin content in the human body are lacking.

Biotin is excreted primarily via urine. The hSMVT regulates the reabsorption of biotin depending on the biotin status, thus reducing renal excretion during biotin deficiency [38]. With regard to the total biotin amount in 24-h urine, biotin is primarily excreted unchanged (>50%) and to a smaller extent as its metabolites bisnorbiotin (13–23%) and biotin sulfoxide (5–13%) [22]. A small proportion (<2%) is excreted via faeces [3, 27].

Assessment of biotin status

Biotin status is frequently determined via concentrations of biotin and its metabolites (e.g., bisnorbiotin, biotin sulfoxide) in serum/plasma/urine or through functional parameters.

Due to impaired enzyme activities, biotin deficiency leads to an increased urinary excretion of certain organic acids [39], particularly 3-hydroxyisovaleric acid (3-HIA) [39, 40] and 3-HIA-carnitine [28]. However, not all subjects develop an increase in 3-HIA concentration after an avidin-induced subclinical biotin depletion [41]. Biotin excretion in 24-h urine often decreases after an avidin-induced depletion [39, 40]. Nevertheless, it is not always possible to distinguish between subjects with and without biotin depletion [41]. As urinary bisnorbiotin and biotin sulfoxide concentrations show a non-linear decrease in the phase of depletion, their suitability as biomarkers of biotin status is limited [39, 40]. Serum concentrations of biotin and its metabolites are considered as non-sensitive parameters of biotin status because significant changes during avidin-induced depletion frequently do not occur [39].

Functional parameters of biotin status include activity changes in biotin-dependent enzymes (e.g., MCC and PCC) as well as altered biotinylation of MCC and PCC in lymphocytes [41]. In a randomised cross-over study including 16 healthy subjects, a reliable distinction between biotin depletion (induced by intake of raw egg white shakes) and adequate biotin status (induced by dietary biotin intake of at least 30 µg/day) was only possible by the biotinylation of lymphocytic MCC and PCC [41].

At present, no gold standard exists for the assessment of biotin status. Moreover, for the currently used biomarkers, no consistent assessment criteria are yet available which allow to classify the measured concentrations or changes in biomarker activities in a deficient, an insufficient or a sufficient biotin status. Thus, biotin status should be determined using a combination of biomarkers. Due to lack of data, it is unclear which combination of biomarkers is the most reliable to determine biotin status. In general, the combination of urinary biomarkers (e.g., 3-HIA) and functional parameters (e.g., degree of biotinylation of lymphocytic MCC and PCC) seems to be reasonable to define adequacy of biotin status.

In studies with healthy subjects, the serum concentrations of biotin ranged between 140 and 356 pmol/l and the serum concentrations of the metabolites ranged between 21 and 591 pmol/l for bisnorbiotin and between 0 and 126 pmol/l for biotin sulfoxide, respectively (n = 15) [39, 42]. The amount of biotin excreted in 24-h urine ranged between 18 and 77 nmol, while the amounts of the metabolites ranged between 11 and 39 nmol for bisnorbiotin, between 5 and 19 nmol for biotin sulfoxide and between 77 and 195 µmol for 3-HIA, respectively (n = 10) [39, 42]. In a more recent investigation, stored samples of control subjects (including also subjects from the former mentioned studies) without reported biotin supplementation were reassessed using improved methods for biomarker determination. According to that investigation, normal daily excretions of biomarkers in 24-h urine were defined as follows: biotin between 19 and 62 nmol, bisnorbiotin between 12 and 54 nmol, biotin sulfoxides between 6 and 15 nmol (defined by the 10th percentile to the 90th percentile, n = 19) and 3-HIA between 39 and 150 µmol (defined by range, n = 17) [40].

However, the performance of frequently used bioassays is variable. Microbial assays failed to determine the concentrations of biotin metabolites, while avidin-binding assays...
frequently underestimate the concentrations of metabolites due to their lower binding affinity to avidin [27]. Avidin-binding assays calibrated with biotin may overestimate free biotin on one hand and may underestimate the total biotin concentration, which also accounts for biotin metabolites, on the other hand [43]. Therefore, a two-step procedure is recommended involving a separation of biotin and its metabolites by chromatographic methods followed by a quantification against reliable standards [27, 40].

**Derivation of the reference values for biotin intake**

**Infants**

The reference values for the intake of biotin for infants aged 0 to under 4 months were derived based on the biotin content of human milk, which is considered to supply the optimal amount of biotin for infants [44, 45]. In human milk, biotin is primarily present in free form [46], in concentrations underlying diurnal fluctuations [47]. The mean biotin content of mature human milk from healthy mothers apparently not consuming biotin supplements during lactation was 4.5 and 5.3 µg/l in studies from Finland (n = 36–200) [48] and Great Britain (n = 27) [49], respectively. Thus, an average content of 4.9 µg/l is supposed. Due to potential racial/ethnic disparities in human milk composition/intake, only studies from European countries were considered. In both studies, mature human milk from mothers of term infants, who were exclusively breastfed, was investigated via microbiological assays. Assuming an average daily intake of human milk of around 750 ml [44, 50–53], biotin intake in an exclusively breastfed infant is approximately 3.7 µg/day. Therefore, the estimated value for an adequate intake of biotin (for explanation of the used term see introduction) for infants aged 0 to under 4 months is set at 4 µg/day (Table 1).

For infants aged 4 to under 12 months, data on the average biotin requirement are lacking. Thus, the reference value for infants aged 0 to under 4 months is used to derive the reference value for infants aged 4 to under 12 months, taking into account the differences in the average body mass and the allometric exponent, thus leading to an estimated value for an adequate intake of biotin of 6 µg/day (Supplementary Table 1). As the requirement of B vitamins depends on the metabolically active body mass, an allometric exponent of 0.75 is assumed due to the association between body mass and metabolic rate according to Kleibers’ law [54, 55].

**Children and adolescents**

No data from balance studies on biotin requirement are available for children and adolescents. Since deficiency symptoms with a usual mixed diet have not been observed so far, the average biotin intake of children and adolescents in German-speaking countries were used to derive estimated values for an adequate intake of biotin. This approach is in line with EFSA [56], which used the reported average biotin intakes among children and adolescents in European countries to set Adequate Intakes for biotin.

Data on biotin intake levels among children and adolescents from Germany and Austria [57–60] are presented in Table 2. No data are available from national examination surveys for children and adolescents from Switzerland. The median intake in some age groups is slightly higher than the reference values published by EFSA [56]. However, data on biotin content in food are frequently based on bioassays with limited specificity for biotin [61, 62]. Furthermore, data on biotin intake are sometimes only available as mean and not as median. The latter,

| Country | Age (years) | n | Biotin intake (µg/d) |
|---------|-------------|---|---------------------|
|         | Male | Female | Male | Female |
| Germany |  |  |  |  |
| 1 to under 4 | 242 | 246 | 28 (20–40) | 25 (18–35) |
| 4 to under 5 | 74 | 75 | 31 (22–42) | 29 (21–41) |
| 6 | 98 | 84 | 36 (18–65) | 30 (17–53) |
| 7 to under 10 | 313 | 274 | 37 (23–71) | 35 (21–70) |
| 10 to under 12 | 195 | 226 | 39 (22–65) | 33 (19–64) |
| 12 | 127 | 131 | 46 (29–261) | 44 (22–136) |
| 13 to under 15 | 222 | 244 | 49 (27–123) | 41 (24–98) |
| 15 to under 18 | 277 | 352 | 61 (29–172) | 43 (23–108) |
|         | 506 | 536 | 45 (42–48) | 36 (34–37) |
| Austria |  |  |  |  |
| 7 to under 10 | 67 | 57 | 48 (24–73) | 45 (34–56) |
| 10 to under 13 | 83 | 81 | 43 (29–57) | 30 (27–32) |
| 13 to under 15 | 19 | 25 | 41 (13–68) | 29 (25–33) |

*a Biotin intake among children in Germany obtained in the Consumption Survey of Food Intake among Infants and Young Children in Germany (2001–2002) via 3-day dietary records; data are presented as median [57] and 10th to 90th percentile [H Heseker 2013, personal communication, 28 January]

b Biotin intake among children and adolescents in Germany obtained in the nutrition module EsKiMo II of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS) (2015–2017) via dietary records; data are presented as median and 10th to 90th percentile [58]

c Biotin intake among adolescents in Germany obtained in the National Nutrition Survey II (2005–2006) via two 24-h recalls; data are presented as median and 95 % CI-median [59]

d Biotin intake among children in Austria obtained in the Consumption Survey of Food Intake among Infants and Young Children in Germany (2010–2012) via 3-day dietary records; data are presented as mean and 95 % CI [60]
however, reflects the intake level more appropriately than the mean value, considering the skewed distribution and outlying values. There is no evidence that the EFSA reference values are insufficient. In the light of this and in view of the wide range of biotin intake levels, the EFSA values [56] were accepted. When using the age groups the D-A-CH reference values are based upon [2], the resulting estimated values for an adequate intake of biotin range from 20 µg/day in children 1 to under 4 years old to 40 µg/day in youths 15 to under 19 years old (Table 1).

Adults

Experimental studies investigating depletion and repletion phases at different dietary biotin intake levels are not available. In this context, it has to be considered that knowledge about dose–response-relationship is scarce and the biotin content of foods is only partially known [62]. Furthermore, data on the assessment of biotin status are insufficient (see “Assessment of biotin status”). Due to the resulting uncertainty in the determination of biotin requirement, only estimated values for an adequate intake of biotin can be derived. As symptoms of deficiency do not occur with a usual mixed diet, the estimated values for an adequate intake of biotin are based on the average intake in the general population, in line with the approach of EFSA [56].

Data on biotin intake levels among adults from Germany and Austria [59, 60, 63] are presented in Table 3. No data are available from national examination surveys for adults from Switzerland. There is no evidence to suggest gender-specific or age-related biotin reference values for adults. Consequently, the estimated value for an adequate intake of biotin was set to 40 µg/day for adults at the age of ≥ 19 years.

Pregnancy

An increased renal 3-HIA excretion has been observed repeatedly during pregnancy [64–66], probably due to changes in glomerular filtration rate or to increased biotin turnover [4]. Results on other status parameters are inconsistent. Renal biotin excretion in pregnant women in the 3rd trimester was lower than in non-pregnant women in one study [43]. Another study did not show any differences in the excretion of biotin and bisnorbiotin between pregnant and non-pregnant women [66]. Since the clinical relevance of these observations remains unclear and deficiency symptoms have not been observed so far, neither in the foetus nor in the mother with a usual mixed diet, no additional requirement for pregnant compared with non-pregnant women is presumed. Thus, for pregnant women, the same intake values of biotin were considered to be adequate as for non-pregnant women.

Lactation

Lactating women probably have an increased turnover and degradation of biotin [66], but clinical symptoms of deficiency have not been observed with a usual mixed diet comprising the diversity of foods (plant- and animal-based foods). A positive association between maternal plasma concentration and biotin concentration in human milk was reported, albeit the latter is much higher and the association was predominantly observed during the first months after delivery [48, 66]. Thus, one can speculate that maternal biotin intake also affects biotin concentration in human milk [47]. Experimental data on the biotin requirement of lactating women are not available. Considering an average biotin loss of approximately 4 µg/day due to lactation (see derivation for infants at the age of 0 to under 4 months), an estimated value for an adequate intake of biotin for lactating women of 45 µg/day is derived.

Table 3 Biotin intake among adults in Germany and Austria

| Country | Age (years) | n   | Male  | Female | Biotin intake (µg/d) |
|---------|-------------|-----|-------|--------|----------------------|
|         |             |     | Male  | Female |                      |
| Germany | 19 to under 25 | 469 | 486   | 46 (45–48) | 39 (37–40) |
|         | 25 to under 35 | 614 | 852   | 48 (46–49) | 42 (41–43) |
|         | 35 to under 51 | 1946| 2648  | 48 (47–49) | 41 (41–42) |
|         | 51 to under 65 | 1460| 1740  | 47 (46–48) | 40 (40–42) |
|         | 65 to 80     | 1165| 1331  | 43 (42–44) | 39 (38–40) |
| Austria | 19 to under 25 | 89  | 181   | 76 ± 75 | 55 ± 69 |
|         | 25 to under 51 | 478 | 856   | 63 ± 55 | 48 ± 38 |
|         | 51 to under 65 | 169 | 245   | 59 ± 51 | 46 ± 32 |
|         | 65 to 80     | 76  | 100   | 36 (33–40) | 43 (34–53) |

*Biotin intake among adults in Germany obtained in the National Nutrition Survey II (2005–2006) via two 24-h recalls; data are presented as median and 95 % CI-median [59]

*Biotin intake among adults in Austria obtained via two 24-h recalls (2014–2016); data are presented as mean and standard deviation [63]

*Biotin intake among adults in Austria obtained via two 24-h recalls (2010–2012); data are presented as mean and 95 % CI [60]
Discussion

Due to the lack of sufficient data on average biotin requirement, the revised D-A-CH reference values for biotin are still estimated values for an adequate intake. Unlike before, the reference values for all age groups are now set as single values and not as ranges (Table 1). However, several uncertainties still exist with regard to specificity of analytical methods to determine biotin content in food.

Foods with a high biotin content include offal, like liver and kidney (cooked beef liver 121 µg/100 g, cooked veal kidney 81 µg/100 g), nuts (hazelnuts 62 µg/100 g, walnuts 36 µg/100 g), sunflower seeds (56 µg/100 g), eggs (25 µg/100 g), soybeans (23 µg/100 g), oatmeal (20 µg/100 g) and mushrooms (cooked champignon 15 µg/100 g, cooked chanterelle 14 µg/100 g). Due to their high consumption, milk and dairy products (cow’s milk 4 µg/100 g, cream cheese with at least 10% fat in dry matter 7 µg/100 g) also contribute to biotin supply [67].

Compared to the previous D-A-CH reference values on biotin, which represent intake ranges in most cases, the current reference values are at the upper end or above the previous ranges in children and at the lower end in infants ≥ 4 months, adolescents, adults and pregnant women. For infants aged 0 to under 4 months, the revised reference value is slightly lower than the former one. For lactating women, the average daily biotin loss due to breastfeeding has now been explicitly considered.

The estimated value for an adequate intake of biotin for infants aged 1 to under 4 years (20 µg/d) is more than three times higher than for the age group 4 to under 12 months (6 µg/d) (Table 1). That is in line with the Adequate Intake values for biotin set by EFSA (6 µg/d for the age group 7 to 11 months and 20 µg/d for children aged 1 to 3 years). Due to an age-related increase in fat-free mass [68], a physiological increase in biotin requirement is expected. However, the marked difference between these two reference values is predominantly explained by the different derivation approaches used to set the reference values for these age groups. For infants 4 to under 12 months, the reference value was extrapolated from the reference value for infants aged 0 to under 4 months using allometric scaling and reference values for body mass. For children 1 to under 4 years, the reference value was derived from median biotin intake values observed in this age group. Similar approaches were used by EFSA [56]. The food intake of children is considerably higher than the infant’s food intake and the food consumed by children contains frequently higher amounts of biotin than human milk.

The current D-A-CH reference values on biotin intake for infants are almost congruent to the values of EFSA [56], IOM [69] and WHO [70], which were derived by a similar approach. For other age groups, the present reference values correspond to the reference values set by EFSA, whereas the D-A-CH reference values are considerably higher than the reference values set by IOM and WHO. However, it has to be considered that the age categories as well as the data basis of derivation differ among the authorities. While D-A-CH and EFSA reference values for subjects ≥ 1 years of age are based on observed biotin intake data, the adequate intake levels set by IOM and WHO are based on extrapolating the intake data from infants under consideration of allometric scaling. Overall, all three authorities derived Adequate Intakes because data on the average requirement are insufficient, what is in line with the present derivation approach. No authority assumed an additional biotin requirement for pregnant compared with non-pregnant women. Moreover, all authorities set higher reference values for lactating compared with non-lactating women due to the loss of biotin during lactation.

Reliable conclusions on the effects of biotin for the primary prevention of nutrition-related chronic diseases such as diabetes mellitus or neurological diseases cannot be drawn as randomised controlled trials on biotin supplementation for primary prevention of such diseases are lacking. Human intervention studies on the effect of biotin supplementation for secondary or tertiary prevention of diabetes mellitus or neurological diseases [71–75] frequently did not observe beneficial effects. However, in most of these studies, a distinction of the biotin effects from concomitant medication is not possible or high-dose biotin supplements were used. Hence, despite potential beneficial effects from biotin on glucose and lipid metabolism [76–81] observed in vitro and in animal studies (e.g., increased expression of glucokinase [78, 82], increased insulin secretion, improved glucose tolerance [78] and increased total beta-cell area relative to pancreas area [78, 79]), no preventive effects of biotin intakes exceeding the current reference values can be actually assumed with regard to nutrition-related chronic diseases. However, EFSA has approved several Article 13 health claims for biotin with regard to the “maintenance of normal skin and mucous membranes”, “maintenance of normal hair”, “contribution to normal psychological functions” and “normal macronutrient metabolism” [83].

Conclusions

Since biotin requirement could not be determined, the revised D-A-CH reference values for an adequate biotin intake are based on the average biotin intake in the general population. This intake is considered to be sufficient
to meet the requirements as symptoms of deficiency do not occur with a usual mixed diet. An adequate biotin supply can be ensured with a balanced diet including biotin-rich foods, such as eggs, nuts, oatmeal and mushrooms. Further research on the precise biotin content in food and on biotin requirement is warranted.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00394-021-02756-0.

**Acknowledgements** The authors thank Professor Sarah Eggert, Manuela Michel, Julia Oleijnik and Professor Hildegard Przyrembel for their valuable suggestions and contribution to the preparation of the revised reference values for biotin intake.

**Author contributions** A.J. conducted the literature research and drafted the manuscript. S.E., M.R. and B.W. revised the draft critically. All authors contributed to the conception of the manuscript and interpreted the data. All authors read and approved the final manuscript.

**Funding** Dr. Alexandra Jungert received an honorarium from the German Nutrition Society (DGE) for developing the first draft of the dietary reference values for biotin intake.

**Declarations**

**Conflicts of interest** The authors declare that they have no conflict of interest.

**Ethics approval** Not applicable.

**Consent to participate** Not applicable.

**Consent for publication** Not applicable.

**Availability of data and material** Not applicable.

**Code availability** Not applicable.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Gesellschaft D, für Ernährung (eds) (2000) Referenzwerte für die Nährstoffzufuhr [Reference values for nutrient intake]. Umschau Verlag, Frankfurt am Main
2. Gesellschaft D, für Ernährung, Österreichische Gesellschaft für Ernährung, Schweizerische Gesellschaft für Ernährung (eds) (2020) Referenzwerte für die Nährstoffzufuhr [Reference values for nutrient intake], 2nd edn, 6th updated version. Bonn, Germany
3. Zempleni J, Wijeratne SSK, Hassan YI (2009) Biotin Biofactors 35(1):36–46. https://doi.org/10.1016/j.biof.8
4. Zempleni J, Mock DM (1999) Biotin biochemistry and human requirements. J Nutr Biochem 10(3):128–138. https://doi.org/10.1016/s0955-2863(98)00095-3
5. Kothapalli N, Camporeale G, Kueh A, Chew YC, Oommen AM, Griffin JB, Zempleni J (2005) Biological functions of biotinylated histones. J Nutr Biochem 16(7):446–448. https://doi.org/10.1016/j.jnutbio.2005.03.025
6. Filenko NA, Kolar C, West JT, Smith SA, Hassan YI, Borgstahl GEO, Zempleni J, Lyubchenko YL (2011) The role of histone H4 biotinylation in the structure of nucleosomes. PLoS ONE 6(1):e16299. https://doi.org/10.1371/journal.pone.0016299
7. Stratton SL, Henrich CL, Matthews NI, Bogusiewicz A, Dawson AM, Horvath TD, Owen SN, Boysen G, Moran JH, Mock DM (2012) Marginal biotin deficiency can be induced experimentally in humans using a cost-effective outpatient design. J Nutr 142(1):22–26. https://doi.org/10.3945/jn.111.151621
8. Matusue S, Kashihara S, Takeda H, Koizumi S (1985) Biotin deficiency during total parenteral nutrition: its clinical manifestation and plasma nonesterified fatty acid level. JPEN J Parenter Enteral Nutr 9(6):760–763. https://doi.org/10.1177/01486785009006760
9. Carlson GL, Williams N, Barber D, Shaffer JL, Wales S, Isherwood D, Shenkin A, Irving MH (1995) Biotin deficiency complicating long-term total parenteral nutrition in an adult patient. Clin Nutr 14(3):186–190. https://doi.org/10.1016/0261-5614(95)80018-2
10. Velázquez A, Zamudio S, Báez A, Murguía-Corral R, Rangel-Peniche B, Carrasco A (1999) Indicators of biotin status: a study of patients on prolonged total parenteral nutrition. Eur J Clin Nutr 44(1):11–16
11. Said HM (2011) Intestinal absorption of water-soluble vitamins in health and disease. Biochem J 437(3):357–372. https://doi.org/10.1042/BJ20110326
12. Sealey WM, Teague AM, Stratton SL, Mock DM (2004) Smoking accelerates biotin catabolism in women. Am J Clin Nutr 80(4):932–935. https://doi.org/10.1093/ajcn/80.4.932
13. Said HM, Redha R, Nylander W (1989) Biotin transport in the human intestine: inhibition by anticonvulsant drugs. Am J Clin Nutr 49(1):127–131. https://doi.org/10.1093/ajcn/49.1.127
14. Mock DM, Mock NI, Nelson RP, Lombard KA (1998) Disturbances in biotin metabolism in children undergoing long-term anticonvulsant therapy. J Pediatr Gastroenterol Nutr 26(3):245–250. https://doi.org/10.1097/00005176-199803000-00002
15. Mock DM, Dyken ME (1997) Biotin catabolism is accelerated in adults receiving long-term therapy with anticonvulsants. Neurology 49(5):1444–1447. https://doi.org/10.1212/wnl.49.5.1444
16. Mock DM (2014) Biotin. In: Ross AC, Caballero B, Cousins RJ (eds) Modern nutrition in health and disease, 11th edn. Lipincott Williams & Wilkins, Philadelphia, pp 390–398
17. Agrawal S, Agrawal A, Said HM (2016) Biotin deficiency enhances the inflammatory response of human dendritic cells. Am J Physiol Cell Physiol 311(3):C386–C391. https://doi.org/10.1152/ajpcell.00141.2016
18. Hynes J, Wolf B (1996) Biotinidase and its roles in biotin metabolism. Clin Chim Acta 255(1):1–11. https://doi.org/10.1016/0009-8911(96)00639-6
19. Wolf B (2005) Biotinidase: its role in biotinidase deficiency and biotin metabolism. J Nutr Biochem 16(7):441–445. https://doi.org/10.1016/j.jnutbio.2005.03.024
20. Wolf B (2011) The neurology of biotinidase deficiency. Mol Genet Metab 104(1–2):27–34. https://doi.org/10.1016/j.ymgme.2011.06.001
27. Zempleni J, Mock DM (1999) Advanced analysis of biotin metabolism and physiology in humans. J Nutr 129(2S):494S-497S. https://doi.org/10.1093/jn/129.2.494S

28. Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Spencer HJ, Moran JH, Mock DM (2011) Urinary excretion of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans. J Nutr 141(3):353–358. https://doi.org/10.3945/jn.110.135772

29. Said HM, Redha R, Nylander W (1988) Biotin transport in the human intestine: site of maximum transport and effect of pH. Gastroenterology 95(5):1312–1317. https://doi.org/10.1016/0016-5085(88)90366-6

30. Said HM, Mock DM, Collins JC (1989) Regulation of intestinal biotin transport in the rat: effect of biotin deficiency and supplementation. Am J Physiol 256(2 Pt 1):G306–G311. https://doi.org/10.1152/ajpgi.1989.256.2.G306

31. Said HM, Redha R, Nylander W (1987) A carrier-mediated, Na+-gradient-dependent transport for biotin in human intestinal brush-border membrane vesicles. Am J Physiol 253(5 Pt 1):G631–G636. https://doi.org/10.1152/ajpgi.1987.253.5.G631

32. Said HM (2009) Cell and molecular aspects of human intestinal biotin absorption. J Nutr 139(1):158–162. https://doi.org/10.3945/jn.108.092023

33. Bowman BB, Selhub J, Rosenberg IH (1986) Intestinal absorption of biotin in the rat. J Nutr 116(7):1266–1271. https://doi.org/10.1093/jn/116.7.1266

34. Mock DM, Malik MI (1992) Distribution of biotin in human plasma: most of the biotin is not bound to protein. Am J Clin Nutr 56(2):427–432. https://doi.org/10.1093/ajcn/56.2.427

35. Chauhan J, Dakshinamurti K (1988) Role of human serum biotinidase in biotin-binding protein. Biochem J 256(1):265–270. https://doi.org/10.1042/bj2560265

36. Lin S, Cronan JE (2011) Closing in on complete pathways of biotin biosynthesis. Mol Biosyst 7(6):1811–1821. https://doi.org/10.1039/c1mb00522b

37. Mock DM (2017) Biotin: from nutrition to therapeutics. J Nutr 147(8):1487–1492. https://doi.org/10.3945/jn.116.238956

38. Balamurugan K, Vaziri ND, Said HM (2005) Biotin uptake by human proximal tubular epithelial cells: cellular and molecular aspects. Am J Physiol Renal Physiol 288(4):F823–F831. https://doi.org/10.1152/ajprenal.00375.2004

39. Mock NI, Malik MI, Stumbo PJ, Bishop WP, Mock DM (1997) Increased urinary excretion of 3-hydroxyisovaleryl and decreased urinary excretion of biotin are sensitive early indicators of decreased biotin status in experimental biotin deficiency. Am J Clin Nutr 65(4):951–958. https://doi.org/10.1093/ajcn/65.4.951

40. Mock DM, Henrich CL, Carnell N, Mock NI (2002) Indicators of marginal biotin deficiency and repletion in humans: validation of 3-hydroxyisovaleric acid excretion and a leucine challenge. Am J Clin Nutr 76(5):1061–1068. https://doi.org/10.1093/ajcn/76.5.1061

41. Eng WK, Giraud D, Schlegel VL, Wang D, Lee BH, Zempleni J (2012) Identification and assessment of markers of biotin status in healthy adults. Br J Nutr 110(2):321–329. https://doi.org/10.1017/S0007114512005065

42. Mock DM, Mock NI (1997) Serum concentrations of bisnorbiotin and biotin sulfoxide increase during both acute and chronic biotin supplementation. J Lab Clin Med 129(3):384–388. https://doi.org/10.1016/S0022-2143(97)90187-6

43. Mishra S, Storer MK, Sherwin CMT, Lewis JG (2005) A simple binding assay for the direct determination of biotin in urine. Clin Chim Acta 360(1–2):60–66. https://doi.org/10.1016/j.cca.2005.04.011

44. Butte NF, Lopez-Alarcon MG, Garza C (2002) Nutrient adequacy of exclusive breastfeeding for the first six months of life. https://www.who.int/nutrition/publications/nut_adequacy_of_exc_bfeeding_eng.pdf. Accessed 04 Feb 2019

45. Bührer C, Genzel-Boroviczény O, Jochum F, Kauth T, Kersting CL, Spencer HJ, Moran JH, Mock DM (2011) Urinary excretion of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans. J Nutr 141(3):353–358. https://doi.org/10.3945/jn.110.135772

46. Mock DM, Mock NI, Langbehn SE (1992) Biotin in human milk: methods, location, and chemical form. J Nutr 122(3):535–545. https://doi.org/10.1093/jn/122.3.535

47. Mock DM, Mock NI, Dankle JA (1992) Secretory patterns of biotin in human milk. J Nutr 122(3):546–552. https://doi.org/10.1093/jn/122.3.546

48. Salmenperä L, Perheentupa J, Pispä JP, Siimes MA (1985) Biotin concentrations in maternal plasma and milk during prolonged lactation. Int J Vitam Nutr Res 55(3):281–285

49. Ford JE, Zecharla A, Murphy J, Brooke OG (1983) Comparison of the B vitamin composition of milk from mothers of preterm and term babies. Arch Dis Child 58(5):367–372

50. Neville MC, Kellar R, Seacat J, Lutes V, Neifert M, Casey C, Allen J, Archer P (1988) Studies in human lactation: milk volumes in lactating women during the onset of lactation and full lactation. Am J Clin Nutr 48(6):1375–1386

51. Grote V, Verduci E, Scaglioni S, Vecchi F, Contarini G, Giovannini M, Koletzko B, Agostoni C (2016) European Childhood Obesity Project. Breast milk composition and infant nutrient intakes during the first 12 months of life. Eur J Clin Nutr 70(2):250–256. https://doi.org/10.1038/ejcn.2015.162

52. Daniels L, Gibson RS, Diana A, Haszard JJ, Rahmannia S, Luftimas DE, Hample D, Shahab-Ferdows S, Reid M, Melo L, Yamers Y, Allen LH, Houghton LA (2019) Micronutrient intakes of lactating mothers and their association with breast milk concentrations and micronutrient adequacy of exclusively breastfed Indonesian infants. Am J Clin Nutr 110(2):391–400. https://doi.org/10.1093/ajcn/nqz047

53. da Costa TH, Haisma H, Wells JC, Spencer HJ, Mander AP, Whitehead RG, Bluck LJ (2010) How much human milk do infants consume? Data from 12 countries using a standardized stable isotope methodology. J Nutr 140(12):2227–2232. https://doi.org/10.1152/jn.00548.2009

54. Kleiber M (1947) Body size and metabolic rate. Physiol Rev 27(4):511–541

55. West GB, Brown JH, Enquist BJ (1997) A general model for the origin of allometric scaling laws in biology. Science 276(5309):122–126
